Book > Third Generation Egfr Inhibitors

Third Generation EGFR Inhibitors

Third Generation EGFR Inhibitors

Detail Book : Third Generation EGFR Inhibitors written by Harun M. Patel, published by Elsevier which was released on 27 November 2018. Download Third Generation EGFR Inhibitors Books now! Available in PDF, ePub and Kindle. Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the development of both covalent irreversible and covalent reversible EGFR Inhibitors. In addition, mechanisms of resistance to third generation inhibitors, and discovery of fourth generation allosteric C797S inhibitors are explored before a discussion of potential future trends. This comprehensive coverage of the design and development of improved analogues to overcome the problems of resistance and toxicity associated with third generation EGFR inhibitors makes Third Generation EGFR Inhibitors a crucial resource for medicinal chemists, drug developers, and researchers investigating cancer therapeutics. Includes full synthetic schemes of all approved and in-trial third generation inhibitors Highlights the emergence of fourth generation EGFR inhibitors and the possibilities of them overcoming constraints of third generation compounds Provides a structural correlation of third and fourth generation EGFR inhibitors, reviewing both their design strategies and typical anticancer activity

GET BOOK
Author : Harun M. Patel
Release Date : 27 November 2018
Publisher : Elsevier
Rating : 4/5 (from 21 users)
Pages : 208
ISBN : 0081026625
Format : PDF, ePUB, KF8, PDB, MOBI, Tuebl
Third Generation EGFR Inhibitors

Third Generation EGFR Inhibitors

Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation

GET BOOK
Molecular Mechanisms of Acquired Resistance to Third generation EGFR TKIs in EGFR T790M mutant Lung Cancer

Molecular Mechanisms of Acquired Resistance to Third generation EGFR TKIs in EGFR T790M mutant Lung Cancer

Abstract Lung cancer represents the leading cause of cancer-related deaths worldwide. Despite great advances in its management with the recent emergence of molecular targeted therapies for non-small-cell lung cancer (NSCLC), relapse of the metastatic disease always occurs within approximately one year. Epidermal growth factor receptor (EGFR) mutant tumours are the

GET BOOK
Frontiers in Anti Cancer Drug Discovery  Volume 11

Frontiers in Anti Cancer Drug Discovery Volume 11

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug

GET BOOK
A Beginner s Guide to Targeted Cancer Treatments

A Beginner s Guide to Targeted Cancer Treatments

The accessible guide to the principles behind new, more targeted drug treatments for cancer Written for anyone who encounters cancer patients, cancer data or cancer terminology, but have no more than a passing knowledge of cell biology. A Beginner's Guide to Targeted Cancer Treatments provides an understanding of how cancer

GET BOOK
Osimertinib and Other Third generation EGFR TKI in EGFR mutant NSCLC Patients

Osimertinib and Other Third generation EGFR TKI in EGFR mutant NSCLC Patients

Abstract Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non-small-cell lung cancer (NSCLC) patients that have acquired the EGFR T790M resistance mutation. Clinical trials have demonstrated the efficacy of osimertinib in this patient population

GET BOOK
Second Line Treatment of Non Small Cell Lung Cancer  Clinical  Pathological and Molecular Aspects of Novel Promising Drugs

Second Line Treatment of Non Small Cell Lung Cancer Clinical Pathological and Molecular Aspects of Novel Promising Drugs

Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therapeutic options are reserved to a

GET BOOK
AACR 2016  Abstracts 1 2696

AACR 2016 Abstracts 1 2696

The AACR Annual Meeting is a must-attend event for cancer researchers and the broader cancer community. This year's theme, "Delivering Cures Through Cancer Science," reinforces the inextricable link between research and advances in patient care. The theme will be evident throughout the meeting as the latest, most exciting discoveries are

GET BOOK
Resistance to Tyrosine Kinase Inhibitors

Resistance to Tyrosine Kinase Inhibitors

The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of

GET BOOK
Adverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring

GET BOOK
Targeted Therapies for Lung Cancer

Targeted Therapies for Lung Cancer

This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights

GET BOOK
Colorectal Cancer

Colorectal Cancer

With international experts sharing their experience and knowledge on these different aspects in the management of colorectal cancer, this book has this opportunity to offer all physicians treating colorectal cancer, as well as researchers, updated information concerning the biology, diagnosis, screening, and treatment of colorectal carcinoma. This book provides a

GET BOOK
Lung Cancer and Personalized Medicine

Lung Cancer and Personalized Medicine

This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current

GET BOOK
Successes and Limitations of Targeted Cancer Therapy

Successes and Limitations of Targeted Cancer Therapy

The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient’s tumor.

GET BOOK
Summers And Winters At Balmwhapple  By The North Sea

Summers And Winters At Balmwhapple By The North Sea

This work has been selected by scholars as being culturally important, and is part of the knowledge base of civilization as we know it. This work was reproduced from the original artifact, and remains as true to the original work as possible. Therefore, you will see the original copyright references,

GET BOOK
P5 eHealth  An Agenda for the Health Technologies of the Future

P5 eHealth An Agenda for the Health Technologies of the Future

This open access volume focuses on the development of a P5 eHealth, or better, a methodological resource for developing the health technologies of the future, based on patients’ personal characteristics and needs as the fundamental guidelines for design. It provides practical guidelines and evidence based examples on how to design,

GET BOOK